Medtronic plcMDT commercially launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients. This happened following the U.S. FDA approval late last year.

Medtronic's MiniMed 670G could reduce the burden on Type 1 diabetes patients, as well as slow diabetes progression by keeping blood glucose levels on target. There are about 1.25 million Americans ...

Editor’s Note: A few weeks ago, a Type 1 diabetes patient authored a blog post about why she didn’t want to switch to Medtronic’s MiniMed 670G billed as the industry’s first hybrid closed-loop insulin ...

The approval of Medtronic's Minimed 670G could reshape the type 1 treatment market next year, but I wouldn't count DexCom out. Its best-in-class technology could position it to capture a significant ...

Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes. Medtronic has announced clinical outcomes for the MiniMed 670G system, ...

The company's announcement notably does not use the term "artificial pancreas," although the technology is a considerably more significant advance from the 530G threshold suspend device of 2013. When ...

Allison Scholl, 16, left, and Eleanor Hedlund, 17, showed off their new Medtronic MiniMed 670G insulin pumps. The two are among the first type 1 diabetes patients in the nation to receive the device, ...

Medtronic plc.'s MDT Diabetes Management segment is dominating the headlines of late. Following the company’s receipt of the CE Mark approval for its advanced continuous glucose monitoring (CGM) ...